Navigation Links
Arno Therapeutics to Deregister its Common Stock under the Exchange Act
Date:5/4/2009

PARSIPPANY, N.J., May 4 /PRNewswire-FirstCall/ -- Arno Therapeutics, Inc. (OTC Bulletin Board: ARNI), a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced that it has voluntarily filed a Form 15 with the Securities and Exchange Commission ("SEC") in order to deregister its common stock under the Securities and Exchange Act of 1934. As a result, effective immediately, Arno's obligation to file periodic and other reports under the Exchange Act is suspended. The Company's decision to deregister its Exchange Act registration is part of its plan to reduce expenses and allocate the costs savings to the further development of its clinical compounds.

The Company's decision is based upon the additional financial and administrative costs and burdens associated with being a public reporting company subject to the regulations promulgated under the Exchange Act. The Company estimates the costs savings to be approximately $300,000 annually that the Company intends to redirect towards advancing its clinical development programs.

The SEC has 90 days to review the Company's Form 15 for compliance with the decertification requirements. However, effective immediately, as a result of the filing of the Form 15, the Company is no longer required to file reports under the Exchange Act, including quarterly reports on Form 10-Q, annual reports on Form 10-K, and current reports on Form 8-K. In addition, certain requirements of the Sarbanes Oxley Act of 2002 will no longer apply to the Company. The Company is eligible to deregister under the Exchange Act because its common stock is held of record by fewer than 300 persons.

About Arno Therapeutics

Arno Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of cancer patients. Arno's lead clinical development compound
'/>"/>

SOURCE Arno Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014 Research ... "Global and China Gel Permeation Chromatography (GPC) Industry ... The Global and China Gel Permeation Chromatography (GPC) ... the current state of the global gel permeation chromatography ... The report provides a basic overview of the industry ...
(Date:8/22/2014)... “Our nation's healthcare system is ... disgrace. Furthermore, every governmental and professional entity that ... state of unorganized dysfunction shares in that enormous ... serve as a device to use in an ... that have accumulated through the years leading to ...
(Date:8/21/2014)... 2014 2014 Deep Research ... a professional and in-depth research report on ... basic Seaweed Fertilizer information, including Seaweed Fertilizer ... as well as industry overview. This research ... market as well as global industry analysis ...
(Date:8/21/2014)... Aug. 21, 2014  Decision Resources Group finds ... and Mexico ... several newly approved agents, the anticipated label extension ... the launch of emerging biologics will substantially increase ... the emerging IL-5 inhibitors will introduce a new dynamic ...
Breaking Biology Technology:Global and China Gel Permeation Chromatography (GPC) Industry Report 2014 25 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3
... -- Further analysis of phase 2 breast cancer data show ... of new metastases, -- Results from 169 patients ... apparent lack of immunogenicity ... Inc.,(Nasdaq: MITI ), a biopharmaceutical company focusing on the ...
... of CD44 found in breast colon, and ... ... (TSX:,ARI), a biotechnology company discovering and developing the next wave of,antibody ... Stem Cell program has successfully completed its first,toxicology study and has ...
... at Transcatheter Cardiovascular Therapeutics 2007 Scientific ... ... Israel and WASHINGTON DC, October 23 /PRNewswire-FirstCall/,-- TopSpin Medical (TASE: ... study of the TopSpin Intravascular,Magnetic Resonance Imaging System During Coronary ...
Cached Biology Technology:Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings 2Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings 3Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings 4Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings 5ARIUS announces cancer stem cell antibody program successfully completes first toxicology study 2ARIUS announces cancer stem cell antibody program successfully completes first toxicology study 3Clinical Study Findings Show Safety and Procedure Success for TopSpin IntraVascular MRI Catheter for the Coronary Arteries 2Clinical Study Findings Show Safety and Procedure Success for TopSpin IntraVascular MRI Catheter for the Coronary Arteries 3
(Date:8/22/2014)... antioxidants and can reduce free radical damage. ... oxidative stress? Jianbo Zhao and co-workers from ... University, China discovered that green tea polyphenol ... apoptosis, indicating green tea polyphenols play a ... oxidative stress. The relevant study has been ...
(Date:8/22/2014)... birds and the bees. But that old expression ... The fertilization process for flowering plants is particularly ... and female reproductive cells. New research from an ... and including Carnegie,s Wolf Frommer, David Ehrhardt, and ... process that guides flowering plant fertilization. It is ...
(Date:8/21/2014)... A new study of American singles found that ... the highest orgasm rates. On average, men experience ... sexual orientation making little difference. For women, however, ... experience orgasm 62.9 percent of the time during ... pattern varies with women,s sexual orientation, with lesbian ...
Breaking Biology News(10 mins):Calcium and reproduction go together 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 4
... India (January 9, 2011) - While age-related vision loss ... 17 million patients today to 55 million by the year ... vision even restored using molecular medicine. ... speaking at the 10th annual meeting and International Conference on ...
... to conserving the UK,s largest and most spectacular terrestrial beetle ... London and the University of York have developed a series ... ginger lures to trap adult beetles and tiny microphones to ... Conservation efforts have been hampered until now because ecologists lacked ...
... RIVERSIDE, Calif. The first commercial crop of a ... of California, Riverside will be harvested beginning later this ... of an induced mutation of W. Murcott mandarin. Originally ... color, easy-peel rind and tangy-sweet flavor traits shared ...
Cached Biology News:Molecular medicine could avert predicted catastrophic vision loss in the aged 2Molecular medicine could avert predicted catastrophic vision loss in the aged 3Ginger is key ingredient in recipe for conserving stag beetles 2Tango mandarins to appear this month in produce aisles 2Tango mandarins to appear this month in produce aisles 3
DAPI: 4', 6-Diamino-2-phenylindole dihydrochloride. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 0.4g/mL DAPI suspended in Antifade....
Takara's Mutan-Super Express Km Kit is designed to achieve site-directed mutagenesis in just one day. It is based on Oligonucleotide-directed Dual Amber (ODA) method, using the advantages of LA (Long...
... Insect Cell Medium are recommended for protein ... combination has been selected based on rapid, ... levels observed specifically with baculoviruses derived from ... Ready-Plaque Sf9 Cells and BacVector Insect Cell ...
...
Biology Products: